基本信息
浏览量:85
职业迁徙
个人简介
As an industry-recognized expert in all facets of API drug development, he was a key driver in the development of numerous drug candidates from early stage through registration and launch, including Primaxin, Fosamax, Cozaar, Emend, and Cancidas. He has in-depth expertise with current global regulatory & compliance requirements, including cGMP, ICH guidelines, PGI assessments, and QbD.
His consulting firm, sp3 Pharma Consulting, specializes in guiding clients through CMC issues on API in all phases of development, with a particular emphasis on integrating science across all areas of pre-clinical development to ensure flawless execution on worldwide regulatory filings.
Dave has 115 publications, 17 patents, and 22 invited lectures, and served on the Board of Editors for Organic Syntheses from 2008-2013, editing volume 90 (2013). Dave was recently honored as the recipient of the 2014 ACS Award in Industrial Chemistry and received the ACS Heroes of Chemistry award in 2006 for leading the team that designed and developed the manufacturing route for the anti-fungal drug Cancidas.
研究兴趣
论文共 348 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2024)
ORGANIC & BIOMOLECULAR CHEMISTRYno. 19 (2023): 4144-4149
引用0浏览0WOS引用
0
0
Dalton Transactionsno. 2 (2023): 394-408
引用0浏览0引用
0
0
Inorganic chemistryno. 32 (2023): 12683-12696
Journal of Engineering Studies and Researchno. 3 (2022): 24-36
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn